DARA BioSciences (DARA) Enters Exclusive Bionect Distribution Agreement with Innocutis
Tweet
Share
E-mailGet Alerts DARA Hot Sheet
Join SI Premium – FREE
DARA BioSciences, Inc. (Nasdaq: DARA) has entered into an exclusive agreement with Innocutis Holdings, LLC ("Innocutis") for U.S. commercial rights to Bionect (hyaluronic acid sodium salt, 0.2%) within the oncology and radiation oncology marketplace.
Bionect is an FDA-approved product indicated for the management of irritation of the skin as well as first and second degree burns. Bionect is currently being promoted and sold by Innocutis in the dermatology market.
Bionect is the third oncology-based agent DARA has licensed to date as part of its strategy to build a focused portfolio of niche opportunity products for the oncology and oncology supportive care markets. DARA expects to launch Bionect in Q212.
Bionect is an FDA-approved product indicated for the management of irritation of the skin as well as first and second degree burns. Bionect is currently being promoted and sold by Innocutis in the dermatology market.
Bionect is the third oncology-based agent DARA has licensed to date as part of its strategy to build a focused portfolio of niche opportunity products for the oncology and oncology supportive care markets. DARA expects to launch Bionect in Q212.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- enVVeno Medical (NVNO) files $100M mixed shelf
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
